Structure of SARS-CoV-2 Spike protein denoting location of Q677P within a disordered loop adjacent to the polybasic (furin) cleavage site (Cited from https://www.medrxiv.org/content/10.1101/2021.02.12.21251658v2.full.pdf).
This variant was first detected in samples collected in New York City in November.
On study found a steady increase (12.3%) in the detection rate from late December to mid-February in New York.
Detection of B.1.526 variant is scattered in the Northeast of US.
The variant has L5F, T95I, D253G, E484K, D614G, and A701V mutations in the spike protein.
D253G resides in the antigenic supersite within the N-terminal domain, which is a target for neutralizing antibodies.
The impact of the E484K mutation on antibody neutralization: neutralizing activities of convalescent plasma or vaccinee sera are lower by 7.7-fold or 3.4-fold, respectively, against the E484K variant (refer to the publication below).
Evaluation of susceptibility of variants identified through global surveillance and in subjects treated with bamlanivimab is ongoing. Pseudovirus harboring the E484K substitution had reduced susceptibility to bamlanivimab. E484K reduced bamlanivimab neutralization >2000-fold.